

SCIENTIFIC REPORTS



OPEN

Oleanolic acid ameliorates high glucose-induced endothelial dysfunction via PPAR δ activation

Zihui Zhang^{1,*}, Manli Jiang^{1,*}, Xinya Xie¹, Haixia Yang¹, Xinfeng Wang¹, Lei Xiao¹ & Nanping Wang^{1,2}

Received: 03 August 2016

Accepted: 02 December 2016

Published: 09 January 2017

Oleanolic acid (3β -hydroxyolean-12-en-28-oic acid, OA) is a pentacyclic triterpenes widely distributed in food, medicinal plants and nutritional supplements. OA exhibits various pharmacological properties, such as hepatoprotective and anti-tumor effects. In this study, we analyzed the effect of OA on endothelial dysfunction induced by high glucose in human vascular endothelial cells (ECs). Western blotting showed that OA attenuated high glucose-reduced nitric production oxide (NO) as well as Akt-Ser⁴⁷³ and eNOS-Ser¹¹⁷⁷ phosphorylation in cultured human umbilical vein ECs (HUVECs). Next, luciferase reporter assay showed that OA activated peroxisome proliferators-activated receptor δ (PPAR δ) activity. Quantitative reverse transcriptase PCR (qRT-PCR) demonstrated that OA increased the expressions of PPAR δ target genes (PDK4, ADRP and ANGPTL4) in ECs. Meanwhile, the induced expressions of PDK4, ADRP and ANGPTL4 by OA were inhibited by GSK0660, a specific antagonist of PPAR δ . In addition, inhibition of PPAR δ abolished OA-induced the Akt-Ser⁴⁷³ and eNOS-Ser¹¹⁷⁷ phosphorylation, and NO production. Finally, by using Multi Myograph System, we showed that OA prevented high glucose-impaired vasodilation. This protective effect on vasodilation was inhibited in aortic rings pretreated with GSK0660. Collectively, we demonstrated that OA improved high glucose-impaired endothelial function via a PPAR δ -mediated mechanism and through eNOS/Akt/NO pathway.

Oleanolic acid (OA), a pentacyclic triterpenoid compound, present in many fruits and vegetables, such as olive leaves, grape, clove and pomegranate flowers¹ exhibits a wide range of pharmacological and biochemical effects^{2,3}. OA has received much attention, and is being marketed as therapeutic drug for the treatment of liver diseases, obesity associated insulin resistance, hypertension, atherosclerosis^{4,5}. Especially, OA has been shown to possess promising anti-diabetic effects in various *in vitro* and *in vivo* models, as well as the ability to reduce blood pressure, blood glucose levels, total cholesterol, triglyceride, low density lipoprotein, and to increase the plasma insulin and high density lipoprotein levels^{1,6}. However, the signal pathways underlying these effects remain to be elucidated.

Substantial clinical and experimental evidence suggest that both diabetes and insulin resistance cause endothelial dysfunction, which is considered the earliest predictive factor for diabetes^{7,8}. One of the main targets against endothelial dysfunction is to improve endothelium-dependent vasodilatation. Nitric oxide (NO) is of critical importance as a mediator of vascular tone and blood pressure. Loss of NO bioavailability is a cardinal feature of endothelial dysfunction^{9,10}. Several factors contribute to loss of NO bioavailability in endothelial dysfunction states, including both reduced NO synthesis and NO scavenging by reactive oxygen species (ROS)¹¹. In ECs, NO is produced by endothelial nitric oxide synthase (eNOS), which catalyzes the oxidation of L-arginine to produce NO. The activity of eNOS can be regulated by a number of post-translational modifications. Among them, protein kinase B (Akt) induces eNOS-Ser¹¹⁷⁷ phosphorylation to modulate endothelial NO production in response to a wide variety of stimuli^{12,13}.

PPAR δ is a member of ligand-activated nuclear receptor transcription factors superfamily, which is ubiquitously expressed with high levels in placenta, skeletal muscles, and adipose tissue. PPAR δ is also expressed in the vascular cells including ECs, smooth muscle cells and macrophages¹⁴. PPAR δ plays important roles in various physiological vascular processes such as apoptosis, survival, angiogenesis and inflammation¹⁵. PPAR δ also

¹Cardiovascular Research Center, Xi'an Jiaotong University, Xi'an, 710061, China. ²The Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, 116044, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to L.X. (email: xiaolei.0122@163.com) or N.W. (email: nanpingwang2003@yahoo.com)




Figure 1. OA improved high glucose-induced NO reduction in BAECs. (a) The chemical structure of OA. (b) HUVECs and BAECs were treated with indicated concentrations of OA for 24 h, and cell viability was measured by MTT. All data were expressed as mean \pm SEM of triplicate experiments. (c) BAECs were preincubated with or without OA (10 μ M) for 12 h, then, treated with high glucose (HG, 30 mM, 12 h), mannitol served as vehicle control to HG. NO was detected by using DAF-FM diacetate (40 \times objective).

promotes vasodilatation by stimulating NO production¹⁶. Recently, we demonstrated an endothelial-protective effect of synthetic PPAR δ agonists in diabetic mice through PI3K/Akt/eNOS signaling¹⁷. In this study, we sought to investigate the effects of a natural product OA on high glucose-impaired NO production and vasorelaxation.

Results

OA improved high glucose-induced NO reduction in BAECs. Endothelial dysfunction is implicated in vascular complications of diabetic patients¹⁸. To study the effects of OA (Fig. 1a) on endothelial function in ECs, we evaluated the cytotoxicity of OA on HUVECs and BAECs firstly by using the MTT assay. Both HUVECs and BAECs were treated with the indicated concentrations (0.1–50 μ M) of OA for 24 h. As shown in Fig. 1b, at a concentration up to 10 μ M caused no decrease in cell viability in either cell types. Thus, this concentration was used in the following cell-based experiments. Then we examined the effect of OA on the endothelial production of NO using the NO-sensitive dye DAF-FM diacetate. As shown in Fig. 1c, treatment with high glucose (HG, 30 mM, 12 h) significantly reduced NO production compared with mannitol control. Pretreatment with OA (10 μ M) effectively restored the NO production in BAECs.

OA attenuated the high glucose-induced impairment of Akt-Ser⁴⁷³ and eNOS-Ser¹¹⁷⁷ phosphorylation. Phosphorylation of Akt at Ser⁴⁷³ plays a critical role in the transduction of insulin signaling and, in turn, phosphorylates its downstream substrate eNOS at Ser¹¹⁷⁷ to increase eNOS activity^{13,19}. In HUVECs, HG treatment suppressed the phosphorylation of both Akt-Ser⁴⁷³ and eNOS-Ser¹¹⁷⁷. However, OA attenuated the suppression of Akt and eNOS phosphorylation by HG (Fig. 2a and b). As shown in Fig. 2c and d, OA could increase the basal levels of Akt-Ser⁴⁷³ and eNOS-Ser¹¹⁷⁷ phosphorylation.

OA activated PPAR δ in ECs. We previously demonstrated a protective effect of PPAR δ on endothelial function in diabetic mice through activating the Akt/eNOS signaling pathway¹⁷. Thus, we examined whether OA activated PPAR δ in ECs. BAECs were transfected with the PPRE-driven luciferase reporter and PPAR δ expression plasmid before exposed to OA. The reporter assay showed that OA increased the luciferase activity of PPAR δ (Fig. 3a). Further, we examined the effects of OA on the expressions of the endogenous PPAR δ target genes including pyruvate dehydrogenase kinase 4 (PDK4), adipose differentiation-related protein (ADRP) and angiopoietin-like protein 4 (ANGPTL4). As shown in Fig. 3b, the mRNA expressions of PDK4, ADRP and ANGPTL4, were increased by OA. In addition, pretreatment with GSK0660, a selective antagonist of PPAR δ , effectively abrogated the induction of PDK4, ADRP and ANGPTL4 by OA (Fig. 3c), suggesting a PPAR δ -specific mechanism.

OA attenuated the high glucose-induced impairment of NO production via PPAR δ . In order to study whether PPAR δ activity is required for the protective effect of OA on NO production against high glucose, HUVECs were pretreated with a selective PPAR δ antagonist GSK0660 and then with OA (10 μ M, 12 h) before the exposure to high glucose. The results demonstrated that, in the presence of GSK0660, OA failed to restore the high glucose impaired NO production (Fig. 4a). We further examined the role of PPAR δ in the Akt and eNOS




Figure 2. OA attenuated the high glucose-induced impairment of Akt-Ser⁴⁷³ and eNOS-Ser¹¹⁷⁷ phosphorylation. (a) HUVECs were pretreated with or without OA (10 μM) for 12 h, and then exposed to normal (5 mM) or high (30 mM) glucose for 12 h. Protein levels of p-eNOS, eNOS, p-Akt and Akt were detected by using western blotting. (b) Quantification of p-eNOS/eNOS and p-Akt/Akt. (c) HUVECs were stimulated with OA (10 μM) for 24 h, cell lysates were analyzed to determine p-eNOS, eNOS, p-Akt and Akt protein levels by using western blot. (d) Quantification of p-eNOS/eNOS and p-Akt/Akt levels in HUVECs. Data were shown as mean ± SEM of independent experiments. *P < 0.05 vs. vehicle control. #P < 0.05 vs. HG.

phosphorylation induced by OA. As shown in Fig. 4b and c, inhibition of PPAR δ activity by GSK0660 significantly diminished the OA-induced eNOS-Ser¹¹⁷⁷ and Akt-Ser⁴⁷³ phosphorylation. In the presence of GSK0660, OA also failed to protect ECs against the high glucose-impaired phosphorylations of Akt and eNOS (Fig. 4d and e).

OA enhanced endothelium-dependent vasodilatation via PPAR δ . Compared with the time-matched vehicle control, OA elicited concentration-dependent relaxations pre-contracted by KCl or phenylephrine in the rat arterial segments (Fig. 5a and b). Next, aortic rings were exposed to high glucose co-incubated with or without OA for 12 h. Acetylcholine-induced endothelium-dependent vasorelaxation was impaired by high glucose (Fig. 5c). HG impaired blood vessel relaxation was attenuated by OA. However, the effect of OA was abolished when the arteries were pre-incubation with GSK0660 (Fig. 5d). These results suggest that OA improves endothelial relaxation and attenuates the high glucose impairment *via* the PPAR δ activation.

Discussion

In this study, we have demonstrated for the first time that OA, as a natural product, can ameliorate the high glucose-triggered endothelial function by activating the nuclear receptor PPAR δ . Previous studies showed that pentacyclic triterpenes from fruits and plants could increase estrogen receptor activities²⁰ and synthetic triterpenes has been identified as ligands for the PPAR γ ²¹. In addition, reporter gene assays showed that oleanolic acid increased PPAR α activity in spontaneously transformed keratinocyte cell line HaCaT and CV-1 cells²². *Punica granatum* flower (PGF) and its component oleanolic acid enhanced the PPAR α reporter activity in human embryonic kidney 293 cells, and this effect was completely suppressed by a selective PPAR α antagonist^{23,24}. We and others have previously demonstrated that synthetic PPAR δ agonists such as GW501516 and GW0742 could




Figure 3. OA activated PPAR δ in ECs. (a) BAECs were transfected with PPRE-luc and PPAR δ plasmids and then treated with OA (10 μ M) for 24 h. The luciferase activities were shown as fold changes in relation to the control. (b) HUVECs were stimulated with OA (10 μ M) for 24 h, PDK4, ADRP and ANGPTL4 mRNA levels were assessed by using qRT-PCR. (c) HUVECs were pretreated with GSK0660 (1 μ M) for 1 h, then exposed to OA (10 μ M) for 24 h, mRNA levels of PDK4, ADRP and ANGPTL4 were assessed. *P < 0.05, **P < 0.01 vs. vehicle control. #P < 0.05, ##P < 0.01 vs. OA.

ameliorate a number of pathological features associated with diabetes and metabolic syndrome. In ECs, these agonists inhibited the expression of pro-inflammatory genes¹⁴. In mouse models for atherosclerosis, synthetic agonists of PPAR δ reduced atherosclerotic lesions²⁵. In obese diabetic mice, the PPAR δ agonists prevented fatty liver by repressing sterol regulatory element binding protein-1 (SREBP1) and improved vascular function^{17,26}. These results clearly indicate that PPAR δ is a promising target for treating metabolic syndrome and related cardiovascular diseases. However, clinical uses of such potent synthetic agonists have been seriously hindered largely due to the claimed cardiovascular adverse effects of PPAR δ ²⁷. Therefore, searching natural compounds with PPAR δ modulating properties and, in particular, vascular protective activity, represent a promising approach for metabolic syndrome and related vascular disorder, also in view of their advantageous effects in endothelial system and obesity prevention²⁸.

Emerging evidence revealed the beneficial effects of OA on endothelial function in vascular disorders associated to metabolic diseases. OA induced vasodilatation in isolated aortas from both normotensive and spontaneously hypertensive rats^{5,29}. NO was involved in the vasodilator responses of OA, and in ECs, OA induced phosphorylation of eNOS-Ser¹¹⁷⁷ to increase NO production³⁰. Further studies have shown that OA increased the phosphorylation of Akt-Ser⁴⁷³ and led to eNOS activation³¹. These observations were largely consistent with our results. However, the mechanisms by which OA regulates Akt/eNOS pathway were poorly understood. Herein, we demonstrated that OA exerts the endothelial protective effects mainly by PPAR δ activation. This notion was supported by its capacity of activating the PPAR-reporter (Fig. 3a) and the induction of multiple endogenous PPAR δ target genes, PDK4, ANGPTL4 and ADRP (Fig. 3b). More importantly, the effects of OA were attenuated by a selective PPAR δ antagonist GSK0660 (Fig. 3c). It remains to be examined whether this pentacyclic triterpenoid serves as a *bona fide* ligand for PPAR δ or enhances the transcriptional activity of PPAR δ by a post-translational modification.

It is well known that exposure to high glucose impairs endothelial functions and decreases the NO production. These deleterious effects are attributed to the inhibition of expression and/or activity of eNOS^{32,33}. PPAR δ agonists could ameliorate the endothelium-dependent vasodilatation impaired by HG via activating PI3K/Akt/eNOS pathway in MAECs¹⁷. In the present study, we found that OA protected endothelial cells from high glucose injury (Fig. 1). This effect could also be inhibited by blocking PPAR δ (Fig. 2). In endothelium-specific PPAR δ deficient mice, both endothelium-dependent relaxations to ACh and endothelium independent relaxations to the NO donor were significantly impaired in the arteries, accompanied by decreased eNOS-Ser¹¹⁷⁷ phosphorylation³⁴.




Figure 4. OA attenuated the high glucose-induced impairment of NO production via PPAR δ . (a) BAECs were pretreated with GSK0660 (1 μ M) for 1 h, and then stimulated with OA (10 μ M) for 12 h by following normal (5 mM) or high (30 mM) glucose medium for 12 h. NO was detected by using DAF-FM probe (40 \times objective). (b) HUVECs were treated as in (a). Protein levels of p-eNOS, eNOS, p-Akt and Akt levels were assessed. (c) Quantification of p-eNOS/eNOS and p-Akt/Akt levels. *P < 0.05 vs. vehicle control, #P < 0.05 vs. OA. (d) HUVECs were pretreated with GSK0660 (1 μ M) for 1 h, then exposed to OA (10 μ M) for 24 h, protein levels of p-eNOS, eNOS, p-Akt and Akt levels were assessed. (e) Quantification of p-eNOS/eNOS and p-Akt/Akt levels. *P < 0.05 vs. vehicle control, #P < 0.05 vs HG and **P < 0.05 vs. OA.

It is suggested that OA restores HG-impaired endothelial function by a PPAR δ -mediated activation of Akt/eNOS signaling pathways. It is worth noting that OA and PPAR δ both possess an anti-oxidative property³⁵. Under oxidative stress, eNOS undergoes uncoupling and produces superoxide rather than NO. GTP cyclohydrolase I (GTPCH I), a rate-limiting enzyme responsible for tetrahydrobiopterin (BH4) *de novo* synthesis, switches eNOS from uncoupled to coupled state to balance the NO and reactive oxygen species (ROS) generations³⁶. GTPCH I protein level was up-regulated by GW501516, as well as the production of BH4 in endothelial progenitor cells³⁷. Thus, the effects of OA on GTPCH I expression and eNOS coupling remain to be investigated.

In summary, this study provided evidence that OA, a component of pentacyclic triterpenes, is a natural modulator of PPAR δ and ameliorates the high glucose impaired endothelial dysfunction. It is suggested that OA has a potential application in the treatment of diabetes related vascular diseases.

Materials and Methods

Ethics statement. The animal experiment was approved by the institutional review board of Xi'an Jiaotong University and performed in accordance with the institutional and national guidelines for the care and use of animals.

Reagents. OA (93.4% in purity) was from ChromaDex (Irvine, CA, USA). The antibodies against phosphorylation eNOS (Ser¹¹⁷⁷), eNOS, phosphorylation Akt (Ser⁴⁷³), Akt were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies against β -actin and horseradish peroxidase (HRP)-conjugated secondary antibody were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Fetal bovine serum (FBS) was from HyClone (Logan, UT, USA). Thiazolyl blue tetrazolium bromide (MTT) was from Sigma-Aldrich (St. Louis, MO, USA).




Figure 5. OA enhanced endothelium-dependent vasodilatation via PPAR δ . Rat aortic arteries were pre-contracted by 60 mM K⁺ (a) or 10 μ M Phe (b) followed by the cumulative addition of vehicle control or OA. Data were shown as mean \pm SEM (n = 3, *P < 0.05, ***P < 0.001 vs. vehicle control). (c) Arterial rings were incubated in medium contained 30 mM glucose in the presence of 10 μ M OA for 12 h, and ACh-induced vasodilatation was tested by using Multi Myograph System. Data are shown as mean \pm SEM (n = 7, *P < 0.05, ***P < 0.001 vs. vehicle control, ###P < 0.05 vs. HG). (d) Arterial rings were incubated with GSK0660 (1 μ M) for 1 h followed by the cumulative addition of OA pre-contracted by Phe (n = 5, ***P < 0.001 vs. vehicle control, ##P < 0.01, ###P < 0.001 vs. OA).

Primer	Forward (5'-3')	Reverse (5'-3')
ADRP	TCAGCTCCATTCTACTGTTCCACC	CCTGAATTTCTGATTGGCACT
ANGPTL4	AAAGAGGCTGCCCGAGAT	GCGCCTCTGAATTACTGTCC
PDK4	AGGTCGAGCTGTTCTCCCGCT	GCGGTCAGGCAGGATGTCAAT
GAPDH	ACCACAGTCCATGCCATCAC	TCCACCACCTGTTGCTGTA

Table 1. List of primer pairs used for qRT-PCR.

4-amino-5-methylamino-2', 7'-difluorofluorescein (DAF-FM) diacetate was from Life Science Ltd. (Oregon, CA, USA). Polyvinylidene difluoride (PVDF) membranes for western blot analysis was purchased from Roche Diagnostics (Mannheim, Germany).

Cell culture. Human umbilical vein endothelial cells (HUVECs) were cultured in medium 199 containing heparin (0.1 mg/ml), acidic fibroblast growth factor (FGF) (10 ng/ml), L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 U/ml) and 20% FBS. Bovine aortic endothelial cells (BAECs) were maintained in Dulbecco's modified Eagle medium (DMEM) with 10% FBS, penicillin (100 U/ml), streptomycin (100 U/ml).

MTT Assay for Cell Viability. Cell viability was evaluated by MTT assay. HUVECs and BAECs were seeded in 96-well plates and cultured until 80% confluence. Then the cells were treated with the indicated concentrations of OA for 24 h before incubation with 5 mg/ml MTT at 37 °C in 5% CO₂ atmosphere for 4 h. Next, the culture medium was removed and the formazan formed in the reaction was dissolved in 150 μ l DMSO. Cell viability was presented as a percentage of the vehicle.

Quantitative Reverse Transcriptase-PCR (qRT-PCR). Total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA), converted to cDNA by iScript cDNA synthesis kit (Bio-rad, Hercules, CA). Real-time PCR was performed by using SYBR Green Supermixes (Bio-rad) and a 7500 Real-time PCR machine (Applied Biosystems, Foster City, CA). The reaction conditions consisted of: stage 1, 95 °C for 10 min; stage 2, 40 cycles of 95 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s, which were concluded by the melting curve analysis process. Fold changes of gene expression were calculated using the 2^{- $\Delta\Delta$ Ct} method. The primer sequences are listed in Table 1. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control.

Western blotting. Cellular proteins were extracted with lysis buffer (50 mM Tris-HCl, pH 7.5, 15 mM EGTA, 100 mM NaCl, 0.1% Triton X-100 and the protease inhibitors). Protein samples were separated on 10% SDS-PAGE gels, transferred to PVDF membranes, and incubated overnight at 4 °C with primary antibodies directed against phosphorylation eNOS (Ser¹¹⁷⁷) (1:1000), eNOS (1:1000), phosphorylation Akt (Ser⁴⁷³) (1:2000), Akt (Ser⁴⁷³) (1:2000) or β -actin (1:5000). After washing blots to remove excessive primary antibody binding, the membranes were incubated for 1 h with horseradish peroxidase (HRP)-conjugated secondary antibody (1:3000) at room temperature, then visualized by the ECL chemoluminescence system.

Plasmids, Transfection and Reporter Assay. The plasmids expressing PPAR δ and PPRE-TK-luciferase reporter contains 3 copies of PPAR-response elements (PPRE) from the acyl-coenzyme A (CoA) oxidase gene were transfected into subconfluent BAECs together with pRSV-gal, a plasmid expressing β -galactosidase by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). 24 hours later, the cells were treated with or without OA. Cell lysates were harvested to measure the luciferase and β -gal activities.

Detection of NO. NO release was measured with using DAF-FM diacetate. Briefly, BAECs seeded on glass coverslips and treated with different stimuli. By the end of treatment, the cells were incubated with DMEM containing DAF-FM (5 μ M) for 30 min in the dark at 37 °C and then washed with PBS. Images were obtained using fluorescence microscopy (Olympus America Inc., NY, USA).

Vascular reactivity. Aortic rings (3 mm) were dissected from Sprague-Dawley rats and incubated with different treatments at 37 °C in 5% CO₂, then mounted in Multi Myograph System (Danish Myo Technology A/S, Denmark) to measure the isometric force. During the whole experiment, the solution was continuously oxygenated with a gas mixture of 95% O₂ plus 5% CO₂. To determine the vasodilatory effect of OA, KCl (60 mM) or phenylephrine (Phe, 10 μ M) was used to constrict arterial rings in advance. After sustained contraction was obtained, the concentration-dependent responses of OA (0.01–100 μ M) were examined. In order to evaluate the role of high glucose, arterial rings were incubated in medium containing 30 mM glucose in the presence or absence of 10 μ M OA to examine the acetylcholine-induced vasodilation.

Statistical analysis. Quantitative data are expressed as mean \pm SEM. Student's *t* test and ANOVA were used to analyze the statistical significance for the differences between two or among more groups, respectively. The dose response curves were analyzed by using two-way ANOVA followed by Bonferroni post-tests. *P* < 0.05 was considered significant. Non-quantitative results were representative of at least three independent experiments.

References

- de Melo, C. L. *et al.* Oleanolic acid, a natural triterpenoid improves blood glucose tolerance in normal mice and ameliorates visceral obesity in mice fed a high-fat diet. *Chemico-biological interactions* **185**, 59–65, doi: 10.1016/j.cbi.2010.02.028 (2010).
- Lee, W., Yang, E. J., Ku, S. K., Song, K. S. & Bae, J. S. Anti-inflammatory effects of oleanolic acid on LPS-induced inflammation *in vitro* and *in vivo*. *Inflammation* **36**, 94–102, doi: 10.1007/s10753-012-9523-9 (2013).
- Jager, S., Trojan, H., Kopp, T., Laszczyk, M. N. & Scheffler, A. Pentacyclic triterpene distribution in various plants - rich sources for a new group of multi-potent plant extracts. *Molecules* **14**, 2016–2031, doi: 10.3390/molecules14062016 (2009).
- Yunoki, K. *et al.* Effect of dietary wine pomace extract and oleanolic acid on plasma lipids in rats fed high-fat diet and its DNA microarray analysis. *Journal of agricultural and food chemistry* **56**, 12052–12058, doi: 10.1021/jf8026217 (2008).
- Madhala, H. P. *et al.* Vascular Endothelium-Dependent and Independent Actions of Oleanolic Acid and Its Synthetic Oleanane Derivatives as Possible Mechanisms for Hypotensive Effects. *PLoS one* **11**, e0147395, doi: 10.1371/journal.pone.0147395 (2016).
- Castellano, J. M., Guinda, A., Delgado, T., Rada, M. & Cayuela, J. A. Biochemical basis of the antidiabetic activity of oleanolic acid and related pentacyclic triterpenes. *Diabetes* **62**, 1791–1799, doi: 10.2337/db12-1215 (2013).
- Mudaui, M., Genis, A., Lochner, A. & Strijdom, H. Endothelial dysfunction: the early predictor of atherosclerosis. *Cardiovascular journal of Africa* **23**, 222–231, doi: 10.5830/CVJA-2011-068 (2012).
- Hadi, H. A. & Suwaidi, J. A. Endothelial dysfunction in diabetes mellitus. *Vascular health and risk management* **3**, 853–876 (2007).
- Salimi, S. *et al.* Association of plasma nitric oxide concentration and endothelial nitric oxide synthase T-786C gene polymorphism in coronary artery disease. *Pathophysiology: the official journal of the International Society for Pathophysiology/ISP* **19**, 157–162, doi: 10.1016/j.pathophys.2012.04.003 (2012).
- Bonetti, P. O., Lerman, L. O. & Lerman, A. Endothelial dysfunction: a marker of atherosclerotic risk. *Arteriosclerosis, thrombosis, and vascular biology* **23**, 168–175 (2003).
- Salisbury, D. & Bronas, U. Reactive oxygen and nitrogen species: impact on endothelial dysfunction. *Nursing research* **64**, 53–66, doi: 10.1097/NNR.000000000000068 (2015).
- Siragusa, M. & Fleming, I. The eNOS signalosome and its link to endothelial dysfunction. *Pflugers Archiv: European journal of physiology* **468**, 1125–1137, doi: 10.1007/s00424-016-1839-0 (2016).
- Heiss, E. H. & Dirsch, V. M. Regulation of eNOS enzyme activity by posttranslational modification. *Current pharmaceutical design* **20**, 3503–3513 (2014).
- Neels, J. G. & Grimaldi, P. A. Physiological functions of peroxisome proliferator-activated receptor beta. *Physiological reviews* **94**, 795–858, doi: 10.1152/physrev.00027.2013 (2014).
- Cheang, W. S., Tian, X. Y., Wong, W. T. & Huang, Y. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. *British journal of pharmacology* **172**, 5512–5522, doi: 10.1111/bph.13029 (2015).
- Quintela, A. M. *et al.* PPARbeta activation restores the high glucose-induced impairment of insulin signalling in endothelial cells. *British journal of pharmacology* **171**, 3089–3102, doi: 10.1111/bph.12646 (2014).
- Tian, X. Y. *et al.* PPARdelta activation protects endothelial function in diabetic mice. *Diabetes* **61**, 3285–3293, doi: 10.2337/db12-0117 (2012).
- Howangyin, K. Y. & Silvestre, J. S. Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. *Arteriosclerosis, thrombosis, and vascular biology* **34**, 1126–1135, doi: 10.1161/ATVBAHA.114.303090 (2014).
- Kolluru, G. K., Siamwala, J. H. & Chatterjee, S. eNOS phosphorylation in health and disease. *Biochimie* **92**, 1186–1198, doi: 10.1016/j.biochi.2010.03.020 (2010).
- Mallavadhani, U. V. *et al.* Three new pentacyclic triterpenes and some flavonoids from the fruits of an Indian Ayurvedic plant *Dendrophthoe falcata* and their estrogen receptor binding activity. *Chemical & pharmaceutical bulletin* **54**, 740–744 (2006).
- Wang, Y. *et al.* A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. *Molecular endocrinology* **14**, 1550–1556, doi: 10.1210/mend.14.10.0545 (2000).

22. Lee, H. K., Nam, G. W., Kim, S. H. & Lee, S. H. Phytocomponents of triterpenoids, oleanolic acid and ursolic acid, regulated differently the processing of epidermal keratinocytes via PPAR-alpha pathway. *Experimental dermatology* **15**, 66–73, doi: 10.1111/j.0906-6705.2005.00386.x (2006).
23. Huang, T. H. *et al.* Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids. *British journal of pharmacology* **145**, 767–774, doi: 10.1038/sj.bjp.0706245 (2005).
24. Li, Y., Qi, Y., Huang, T. H., Yamahara, J. & Roufogalis, B. D. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties. *Diabetes, obesity & metabolism* **10**, 10–17, doi: 10.1111/j.1463-1326.2007.00708.x (2008).
25. Ding, Y., Yang, K. D. & Yang, Q. The role of PPARdelta signaling in the cardiovascular system. *Progress in molecular biology and translational science* **121**, 451–473, doi: 10.1016/B978-0-12-800101-1.00014-4 (2014).
26. Qin, X. *et al.* Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. *Hepatology* **48**, 432–441, doi: 10.1002/hep.22334 (2008).
27. Saag, K. G. *et al.* Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med* **357**, 2028–2039, doi: 10.1056/NEJMoa071408 (2007).
28. Ehrenborg, E. & Skogsberg, J. Peroxisome proliferator-activated receptor delta and cardiovascular disease. *Atherosclerosis* **231**, 95–106, doi: 10.1016/j.atherosclerosis.2013.08.027 (2013).
29. Rodriguez-Rodriguez, R., Herrera, M. D., Perona, J. S. & Ruiz-Gutierrez, V. Potential vasorelaxant effects of oleanolic acid and erythrodiol, two triterpenoids contained in 'orujo' olive oil, on rat aorta. *The British journal of nutrition* **92**, 635–642 (2004).
30. Rodriguez-Rodriguez, R. *et al.* Oleanolic acid induces relaxation and calcium-independent release of endothelium-derived nitric oxide. *British journal of pharmacology* **155**, 535–546, doi: 10.1038/bjp.2008.289 (2008).
31. Rodriguez-Rodriguez, R. Oleanolic acid and related triterpenoids from olives on vascular function: molecular mechanisms and therapeutic perspectives. *Curr Med Chem* **22**, 1414–1425 (2015).
32. Ding, Y., Vaziri, N. D., Coulson, R., Kamanna, V. S. & Roh, D. D. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. *American journal of physiology. Endocrinology and metabolism* **279**, E11–17 (2000).
33. Du, X. L. *et al.* Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. *The Journal of clinical investigation* **108**, 1341–1348, doi: 10.1172/JCI11235 (2001).
34. d'Uscio, L. V. *et al.* Mechanisms of vascular dysfunction in mice with endothelium-specific deletion of the PPAR-delta gene. *Am J Physiol Heart Circ Physiol* **306**, H1001–1010, doi: 10.1152/ajpheart.00761.2013 (2014).
35. Fan, Y. *et al.* Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. *Arteriosclerosis, thrombosis, and vascular biology* **28**, 315–321, doi: 10.1161/ATVBAHA.107.149815 (2008).
36. Wang, S. *et al.* Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. *Hypertension* **52**, 484–490, doi: 10.1161/HYPERTENSIONAHA.108.112094 (2008).
37. He, T., Smith, L. A., Lu, T., Joyner, M. J. & Katusic, Z. S. Activation of peroxisome proliferator-activated receptor- δ enhances regenerative capacity of human endothelial progenitor cells by stimulating biosynthesis of tetrahydrobiopterin. *Hypertension* **58**, 287–294, doi: 10.1161/HYPERTENSIONAHA.111.172189 (2011).

Acknowledgements

This study was supported by grants from the National Science Foundation of China (31430045, 81300242, 30881220108005, and 81470373).

Author Contributions

Zhang, Z. and Jiang, M. performed most of experiments, analyzed the data and wrote the draft of the manuscript. Xie, X. and Wang, X. performed a part of experiments. Yang, H. analyzed the chemical structure and revised the manuscript. Xiao, L. and Wang, N. designed the experiments, provided funding, and wrote the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhang, Z. *et al.* Oleanolic acid ameliorates high glucose-induced endothelial dysfunction via PPAR δ activation. *Sci. Rep.* **7**, 40237; doi: 10.1038/srep40237 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017